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This paper is a case presentation and discussion of a 12-year-old
boy previously in excellent health who presents with dematomal
herpes zoster. Although not unheard of, the occurrence of herpes
zoster in the pediatric population is infrequent. This case provides
the opportunity to address many of the aspects of herpes zoster that
are unique to the pediatric population including epidemiology,
pathophysiology, management and course, and the potential im
pact of the live attenuated varicella vaccine, recently approved for
the prevention of the primary vance/la infection, chickenpox.
Case Report
A twelve-year-old Chinese-caucasian male was well and in his
usual state of excellent health, when on one Friday morning while
at school he complained of a sharp. tingling pain on the back of his
neck. The school nurse noticed a small papular, erythematous
eruption in the region of the neck from which the patient had
complained. The patient was found to have a low grade fever as well.
His mother was notified and the patient was sent home. The mother
attempted to relieve the symptoms by applying Lanacaine ointment
and calamine lotion without much success. The next morning,
Saturday, the extent of the eruption had spread following the C3
dermatome down the left side of his neck and up to the back of his
hairline. The eruption had become vesicular and more erythematous.
The patient also reported some weakness in his left arm. The patient
was brought into the clinic and upon further questioning denied any
recent outdoor treks, travels, changes in clothes, detergents, or
soaps. The mother reported that the patient had had a mild case of
chickenpox at a very early age and has otherwise been extremely
healthy without any recent increased frequency of illnesses, weight
loss, or night sweats.
On physical exam, the patient was a well developed 12-year-old
male, nontoxic appearing but in moderate distress due to the painful
lesions on the left side of his neck. Vital signs were within normal
limits. The lesions on the left side of his neck had an erythematous,
mildly edematous base with superimposed oval-round vesicles.
The eruption extended down the left side of the neck to the mid
clavicular region with a few isolated lesions over the acromio
clavicular region. It extended up to his hairline with some scalp
involvement. Eyes and ears were not involved. There was a mild
degree of weakness on flexion against resistance on his left upper
extremity. Sensory and coordination were intact. The remainder of
the exam was entirely within normal limits.
A presumptive diagnosis of herpes zoster was made based on the
history and physical findings. No confirmatory tests such as a
Tzanck preparation, viral culture, biopsy. or immunoflourescence
were performed. Based on the patient’s history of excellent health,
a workup of the patient’s immunocompetence was deemed unnec
essary. The patient was started on oral acyclovir. On follow up five
days later, there was marked improvement. The number of lesions
had decreased markedly and the existing lesions had dried and
crusted over. The patient reported that he had regained his strength
in his left arm.
Discussion
The recognition and diagnosis of dermatomal herpes zoster in
adults and children is straightforward. Although not unheard of, the
occurrence of herpes zosterin the pediatric population is infrequent.
This case provides the opportunity to address many of the aspects
of herpes zoster that are unique to the pediatric population.
Epidemiology
With an estimated 3 million cases of chickenpox a year in the U.S.,
greater than 95% occurring in children and adolescents, the preva
lence of primary varicella zoster virus (VZV) exposure is nearly
universal within the pediatric population.’
In contrast, the incidence of herpes zoster. which is the manifes
tation of the reactivabon of latent varicelia zoster virus from within
the dorsal root ganglia. is very low in childhood. In individuals less
than 10 years of age, there is an estimated incidence of 0.74/1000
patients versus an estimated annual rate of 3.4/1000 for the general
population.2
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There are several conditions or circumstances
in children that have a higher incidence of
herpes zoster than the general pediatric popula
tion (See Table 1). Acute lymphocytic leukemia
(ALL) patients or children receiving immuno
suppressive therapy, have the highest incidence
of herpes zoster within the pediatric population.
It has been estimated that herpes zoster occurs in
22-25% of children with ALL and a prior his
tory ofchickenpox . Immunocompromised chil
dren are at greater risk for disseminated herpes
zoster viith visceral involvement, particularly
VZV pneumonia, and a 20 % mortality.2Chil
dren with HIV are commonly afflicted with
herpes zoster but it rarely becomes dissemi
nated. Herpes zoster occurring in infants is
strongly associated with in-utero exposure to
VZV.4 Children afflicted with chickenpox, the
primary infection of VZV, at less than 1 year of
age, have a greater predisposition for develop
ing herpes zoster later on in their childhood,
particularly before the age of 745
The dermatomal distribution of the cases of
herpes zoster within the general pediatric popu
lation is similar to adults with the preponder
ance of cases of occurring between T2-L2.
However, Terada et al. found some interesting
variations in dermatomal distribution when the
pediatric population was broken down by age.
In children less than 7 years of age, the involve
ment of cervical and cranial nerve dermatomes
was 41.7 % and 25 %, respectively. In children
greater than 7 years of age, 78.9 % involved the
thoracic dermatomes. Terada et al hypothesized
that these findings may reflect the changing
body proportions of growing children. If this is
the case, Terada further hypothesized that the
dermatomal site of herpes zoster may be a
reflection of the region of highest preponder
ance of exanthems during the primary infection
with VZV, chickenpox .
Pathophysiology
It is firmly established that following primary
infection, VZV remains in a latent state within
the dorsal root ganglia. Herpes zoster represents
the reactivation of this latent virus from within
a particular ganglion. The epidemiology of
herpes zoster indicate that latency and reactiva
tion is dependent on both host and viral factors.
Attempts to elicit the pathogenesis of herpes
zoster have been confounded by the fact that
human beings are the only known harborers of
Presenting findings; eruption predominantly restricted to C3 dermatome with a few isolated
lesions on left shoulder.
Table 1.—Risk Factors for Herpes zoster in children
1) ALL and other malignancies.
2) lmmunocompromised (treatments, HlV).
3) In-Utero varicella exposure.
4) Chicken Pox at age < 1 yr.
Patient 5 days later status-post oral acyclovir. Eruption markedly improved, remaining lesions
dry and crusted over.
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VZV. The high incidence of herpes zoster in the
immunocompromised indicates that the immune system plays a role
in maintaining latency, particularly cellular immunity.6The higher
incidence of Herpes zoster in adults, it is believed, may reflect a
natural decline in cellular immunity with age.6
The occulTence of herpes zoster in children is even more puzzling.
In some cases, it may be the result of an immunocompromising
illness or therapy, but in healthy children, it remains a mystery.
Analysis of blood drawn from healthy children with herpes zoster
often resembles that of a primary infection with high titers of
Natural Killer Cells and 1gM antibodies despite having been previ
ously exposed to the virus. It has been hypothesized that this
apparent loss of immunologic memory may be due to an incomplete
or immature immunologic response at the time of primary exposure
to the VZV. An immature immune response has been the long-held
belief for the mechanism behind the higher frequencies of herpes
zoster in infants exposed to VZV in-utero and in children who had
a primary VZV infection at less than 1 year of age. In other children,
the occurrence of herpes zoster may reflect an incomplete immune
response to perhaps a mild primary VZV intection. However, a
relationship between herpes zoster and the severity ot primary VZV
infection has not been established.
Studies of immunologic memory status have revealed that VZV
specific cellular immunity is enhanced by frequent exposure to
VZV.3’6It is hypothesized that multiple exogenous exposures to, or
subclinical endogenous reactivation of. the VZV may serve as a
booster to the immunologic system and may aid in maintaining the
virus in their latent state within the ganglia.
Management and Treatment
In the management and treatment of herpes zoster in children, the
pediatrician may be faced with several questions that are unique to
the pediatric population.
• Should anti-viral medications such as acyclovir (Zovirax).
famcyclovir (Famvir), or valacyclovir hydrochloride (Valtrex)
be employed? Or are there toxicities or precautions unique to
the pediatric population that one should be aware of?
• Should a healthy child with herpes zoster be further evaluated
for other immunocompromising illnesses?
• Is herpes zoster a precursor to a malignancy?
• Will there be any persistent neuralgia as may occur in adults?
• And the inevitable question of all parents of school age chil
dren, is the child contagious, should he stay home from school?
In most cases, herpes zoster in otherwise healthy children runs a
benign course, requiring only supportive treatment with non-aspirin
analgesics and local wound care. The exceptions to this are herpes
zoster involving the first branch of the trigeminal nerve or within the
ear canal. Forty percent of patients with initial zoster lesions
occurring on the forehead and eighty percent with initial lesions on
the tip of the nose, will develop ocular involvement.8Because ocular
and auditory involvement may lead to significant permanent im
pairment, more aggressive therapy may be warranted.
The indications for and usage of antiviral agents in the manage
ment of pediatric herpes zoster is still quite controversial. The safety
and efficacy in children has not been established for famcyclovir
and valacyclovir hydrochloride. There has been considerably more
experience with the use of acyclovir. However, it still has not been
adequately studied for the use on children less than 2 years of age.
In 1992. the FDA approved the use of oral acyclovir for the
treatment of varicella infections in otherwise healthy children. In
1993. the American Academy of Pediatricians (AAP) released the
following recommendations tor the use of oral acyclovir in varicella
infections:
In their review of the available literature and own clinical experi
ence, Rothe et al recommended the following guidelines, specifi
cally for the treatment of Herpes zoster in children:
In children, acyclovir appears to be better tolerated than adults.8
Possible side effects are nausea and vomiting which occurs in less
than 8 % and 3 % of the pediatric population, respectively. “ There
is even lower incidence of diarrhea, headaches, and cutaneous
eruptions. Dehydration and over-dosage may lead to renal precipi
tation. Renal function should be closely monitored in the neonate
population.”
Herpes zoster eruptions are contagious to individuals not previ
ously exposed to the varicella virus. However, it is estimated to be
only one third as contagious as primary varicella infection.’2Trans
mission by direct contact with the lesions has been established.
Respiratory transmission, the main mode of transmission in primary
varicella infection, has not been conclusively excluded as a mode of
transmission to susceptible individuals.
Although there is a higher incidence of herpes zoster in childhood
malignancies, the reverse has not been found to be true. No associa
tion between herpes zoster and subsequent cancer has been found.
Prospective studies of individuals with herpes zoster have shown
the same incidence of malignancies as the general population.’2
From this information, it appears that further evaluation on an
otherwise healthy child is unnecessary unless dictated by their
history.
The occurrence of post-herpetic neuralgia in children is still
questioned. In general. it can be said that herpes zoster has a much
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American Academy of Pediatrics Recommendations.9
1) Oral acyclovir is not recommended routinely for uncomplicated varicella in otherwise
healthy children
2) for children at increased risk of severe varicella or its complications (older than 13 yrs.,
those receiving chronic corticosteroids or aspirin therapy, those with chronic cutane
ous or pulmonary diseases), oral acyclovir should be considered, if it can be initiated
within 24 hours of the rash.
3) When given, oral acyclovir should be administered for 5 days. The patient must
maintain adequate fluid intake.
4) Primary varicelia or recurrent zoster in immunocompromised and virus mediated
complications of varicella in normal hosts should be treated with intravenous acyclovir.
5) Oral treatment is not recommended in pregnant adolescents with uncomplicated
disease.
6) Otral acyclovir may be considered for household contacts because they usually have
more severe illness.
Recommendations for Acyclovir for Treatment of Herpes zoster in Children.8
1) Ocular zoster in adolescents and children and pregnancy: treat with oral acyclovir and
refer to an opthalmologist for continuing care.
2) Zoster in adolescents: treat with oral acyclovir if identified within 72 hours of exanthem.
3) Zoster in children: do not treat, as it is relatively benign.
4) Zoster in Atopic patients receiving systemic corticosteroids: Do not treat, as it is
relatively benign.
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milder course in children than adults with a minimal risk of post
herpetic neuralgia, the incidence of which is as high as 43% in some
adult studies.6 In their study of childhood zoster over a 20 year
period. Guess et al found no incidence of post-herpetic neuralgia.5
Live Attenuated Varicelle Vaccine
With the recent AAP recommendation of the live attenuated
varicelia vaccine for the prevention of primary varicella infection
(chickenpox), there has been much discussion on its potential
impact on the incidence of herpes zoster. It was initially hoped that
with the eradication ot primary varicella infection by the vaccine,
there would be a similar impact upon herpes zoster. However,
further studies of the attenuated vaccine virus have shown that it,
too, can cause latent infection within the ganglia and dermatomal
zoster eruptions upon reactivation.’3As a result, there has been a
growing concern that there may possibly be an increase in the
incidence ofherpes zoster as a result of the new vaccination policies.
Current U.S. studies show no increased incidence of herpes zoster
in heathy immunized children. A 4 year follow-up study of 548
children with ALL immunized against varicella actually showed a
decrease in the incidence of herpes zoster.’3 This finding was
significant in that these patients are normally considered at highest
risk for varicella reactivation.
There may be several explanations for the decreased incidence of
zoster after vaccination. One is the virus is attenuated. Another is
that the exanthem of primary varicella may be necessary for the
virus to gain access to the sensory nerves and reside within the dorsal
ganglion region.
The varicella vaccine may play another role in the prevention of
herpes zoster. Immunologic studies of adults receiving vaccination
have shown higher levels of VZV specific T-cell levels.6 These
findings imply that the varicella vaccine may have the potential of
being used as an immunologic booster with the hope of preventing
herpes zoster in adult populations as well.
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